MedTrace Logo

Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab

NCT02107131 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-12-19

Study results available
· View outcomes & findings →

Summary

Performance assessment testing may be a useful tool to evaluate the impact of ranibizumab on day-to-day visual function in patients with Diabetic Macular Edema (DME).

Conditions

Interventions

DRUG

Intravitreal ranibizumab 0.3mg

Sponsors & Collaborators

  • California Retina Consultants

    lead OTHER

Principal Investigators

  • Gabriel Gordon, PhD · California Retina Consultants

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-13
Primary Completion
2017-05-15
Completion
2017-05-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02107131 on ClinicalTrials.gov